nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0261	0.0367	CbGbCtD
Lansoprazole—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0236	0.0332	CbGbCtD
Lansoprazole—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0236	0.0332	CbGbCtD
Lansoprazole—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0226	0.0318	CbGbCtD
Lansoprazole—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0175	0.0246	CbGbCtD
Lansoprazole—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0166	0.0233	CbGbCtD
Lansoprazole—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0166	0.0233	CbGbCtD
Lansoprazole—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0164	0.023	CbGbCtD
Lansoprazole—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0154	0.0216	CbGbCtD
Lansoprazole—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0151	0.0212	CbGbCtD
Lansoprazole—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0142	0.02	CbGbCtD
Lansoprazole—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0142	0.02	CbGbCtD
Lansoprazole—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0139	0.0196	CbGbCtD
Lansoprazole—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0139	0.0196	CbGbCtD
Lansoprazole—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0136	0.0191	CbGbCtD
Lansoprazole—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0128	0.0181	CbGbCtD
Lansoprazole—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0128	0.018	CbGbCtD
Lansoprazole—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0128	0.018	CbGbCtD
Lansoprazole—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0126	0.0177	CbGbCtD
Lansoprazole—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0126	0.0177	CbGbCtD
Lansoprazole—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0124	0.0175	CbGbCtD
Lansoprazole—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0124	0.0175	CbGbCtD
Lansoprazole—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0121	0.017	CbGbCtD
Lansoprazole—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.012	0.0169	CbGbCtD
Lansoprazole—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0117	0.0165	CbGbCtD
Lansoprazole—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0117	0.0165	CbGbCtD
Lansoprazole—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0117	0.0164	CbGbCtD
Lansoprazole—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0116	0.0163	CbGbCtD
Lansoprazole—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0116	0.0163	CbGbCtD
Lansoprazole—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0112	0.0158	CbGbCtD
Lansoprazole—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0108	0.0151	CbGbCtD
Lansoprazole—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0106	0.0149	CbGbCtD
Lansoprazole—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0106	0.0149	CbGbCtD
Lansoprazole—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0106	0.0148	CbGbCtD
Lansoprazole—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0106	0.0148	CbGbCtD
Lansoprazole—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0101	0.0142	CbGbCtD
Lansoprazole—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00999	0.014	CbGbCtD
Lansoprazole—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00973	0.0137	CbGbCtD
Lansoprazole—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0097	0.0136	CbGbCtD
Lansoprazole—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0097	0.0136	CbGbCtD
Lansoprazole—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00941	0.0132	CbGbCtD
Lansoprazole—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00914	0.0128	CbGbCtD
Lansoprazole—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00887	0.0125	CbGbCtD
Lansoprazole—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00877	0.0123	CbGbCtD
Lansoprazole—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00877	0.0123	CbGbCtD
Lansoprazole—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00851	0.012	CbGbCtD
Lansoprazole—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00851	0.012	CbGbCtD
Lansoprazole—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00841	0.0118	CbGbCtD
Lansoprazole—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00816	0.0115	CbGbCtD
Lansoprazole—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00802	0.0113	CbGbCtD
Lansoprazole—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00802	0.0113	CbGbCtD
Lansoprazole—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00791	0.0111	CbGbCtD
Lansoprazole—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00744	0.0105	CbGbCtD
Lansoprazole—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00744	0.0105	CbGbCtD
Lansoprazole—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00673	0.00946	CbGbCtD
Lansoprazole—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00673	0.00946	CbGbCtD
Lansoprazole—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00631	0.00888	CbGbCtD
Lansoprazole—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00581	0.00817	CbGbCtD
Lansoprazole—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00564	0.00793	CbGbCtD
Lansoprazole—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0051	0.00717	CbGbCtD
Lansoprazole—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0051	0.00717	CbGbCtD
Lansoprazole—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00489	0.00687	CbGbCtD
Lansoprazole—ATP4A—blood plasma—acquired immunodeficiency syndrome	0.0033	0.0739	CbGeAlD
Lansoprazole—ATP4B—digestive system—acquired immunodeficiency syndrome	0.00291	0.0653	CbGeAlD
Lansoprazole—MAPT—retina—acquired immunodeficiency syndrome	0.00243	0.0545	CbGeAlD
Lansoprazole—CYP4A11—digestive system—acquired immunodeficiency syndrome	0.00157	0.0352	CbGeAlD
Lansoprazole—MAPT—spinal cord—acquired immunodeficiency syndrome	0.00157	0.0351	CbGeAlD
Lansoprazole—CYP4A11—vagina—acquired immunodeficiency syndrome	0.00139	0.0311	CbGeAlD
Lansoprazole—ATP4A—digestive system—acquired immunodeficiency syndrome	0.00127	0.0284	CbGeAlD
Lansoprazole—ATP4A—blood—acquired immunodeficiency syndrome	0.00121	0.0271	CbGeAlD
Lansoprazole—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00115	0.0258	CbGeAlD
Lansoprazole—CYP2C18—digestive system—acquired immunodeficiency syndrome	0.00104	0.0233	CbGeAlD
Lansoprazole—MAPT—brain—acquired immunodeficiency syndrome	0.00101	0.0226	CbGeAlD
Lansoprazole—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00101	0.0225	CbGeAlD
Lansoprazole—ATP4A—nervous system—acquired immunodeficiency syndrome	0.000981	0.022	CbGeAlD
Lansoprazole—MAPT—lymph node—acquired immunodeficiency syndrome	0.000976	0.0219	CbGeAlD
Lansoprazole—ATP4A—central nervous system—acquired immunodeficiency syndrome	0.000945	0.0211	CbGeAlD
Lansoprazole—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000941	0.0211	CbGeAlD
Lansoprazole—CYP2C18—vagina—acquired immunodeficiency syndrome	0.000921	0.0206	CbGeAlD
Lansoprazole—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000894	0.02	CbGeAlD
Lansoprazole—ATP4A—brain—acquired immunodeficiency syndrome	0.00075	0.0168	CbGeAlD
Lansoprazole—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000681	0.0153	CbGeAlD
Lansoprazole—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00067	0.015	CbGeAlD
Lansoprazole—CYP1B1—skin of body—acquired immunodeficiency syndrome	0.000631	0.0141	CbGeAlD
Lansoprazole—CYP1B1—lymphoid tissue—acquired immunodeficiency syndrome	0.000511	0.0114	CbGeAlD
Lansoprazole—CYP1B1—digestive system—acquired immunodeficiency syndrome	0.000505	0.0113	CbGeAlD
Lansoprazole—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000482	0.0108	CbGeAlD
Lansoprazole—CYP1B1—blood—acquired immunodeficiency syndrome	0.000481	0.0108	CbGeAlD
Lansoprazole—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000446	0.00999	CbGeAlD
Lansoprazole—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000443	0.00992	CbGeAlD
Lansoprazole—CYP2C19—blood—acquired immunodeficiency syndrome	0.000422	0.00945	CbGeAlD
Lansoprazole—CYP1B1—lung—acquired immunodeficiency syndrome	0.000422	0.00944	CbGeAlD
Lansoprazole—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000391	0.00876	CbGeAlD
Lansoprazole—CYP1B1—nervous system—acquired immunodeficiency syndrome	0.000391	0.00875	CbGeAlD
Lansoprazole—CYP1B1—central nervous system—acquired immunodeficiency syndrome	0.000376	0.00842	CbGeAlD
Lansoprazole—CYP2C8—blood—acquired immunodeficiency syndrome	0.000369	0.00825	CbGeAlD
Lansoprazole—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000362	0.0081	CbGeAlD
Lansoprazole—ABCG2—blood—acquired immunodeficiency syndrome	0.000358	0.00802	CbGeAlD
Lansoprazole—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000357	0.00799	CbGeAlD
Lansoprazole—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000347	0.00776	CbGeAlD
Lansoprazole—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000345	0.00773	CbGeAlD
Lansoprazole—CYP1A2—blood—acquired immunodeficiency syndrome	0.000345	0.00772	CbGeAlD
Lansoprazole—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000344	0.00769	CbGeAlD
Lansoprazole—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000342	0.00765	CbGeAlD
Lansoprazole—CYP1A1—blood—acquired immunodeficiency syndrome	0.00034	0.00762	CbGeAlD
Lansoprazole—ABCG2—vagina—acquired immunodeficiency syndrome	0.000332	0.00744	CbGeAlD
Lansoprazole—CYP2C9—blood—acquired immunodeficiency syndrome	0.000327	0.00733	CbGeAlD
Lansoprazole—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000315	0.00706	CbGeAlD
Lansoprazole—ABCG2—lung—acquired immunodeficiency syndrome	0.000314	0.00703	CbGeAlD
Lansoprazole—CYP1A2—lung—acquired immunodeficiency syndrome	0.000302	0.00677	CbGeAlD
Lansoprazole—CYP1B1—brain—acquired immunodeficiency syndrome	0.000299	0.00668	CbGeAlD
Lansoprazole—CYP1A1—lung—acquired immunodeficiency syndrome	0.000298	0.00668	CbGeAlD
Lansoprazole—CYP1B1—lymph node—acquired immunodeficiency syndrome	0.000289	0.00646	CbGeAlD
Lansoprazole—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000276	0.00618	CbGeAlD
Lansoprazole—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000266	0.00595	CbGeAlD
Lansoprazole—ABCB1—retina—acquired immunodeficiency syndrome	0.000264	0.00591	CbGeAlD
Lansoprazole—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000262	0.00587	CbGeAlD
Lansoprazole—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000258	0.00577	CbGeAlD
Lansoprazole—CYP3A4—blood—acquired immunodeficiency syndrome	0.00025	0.00559	CbGeAlD
Lansoprazole—CYP2D6—blood—acquired immunodeficiency syndrome	0.000246	0.0055	CbGeAlD
Lansoprazole—CYP2C8—brain—acquired immunodeficiency syndrome	0.000229	0.00512	CbGeAlD
Lansoprazole—ABCG2—brain—acquired immunodeficiency syndrome	0.000222	0.00498	CbGeAlD
Lansoprazole—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000215	0.00481	CbGeAlD
Lansoprazole—CYP1A1—brain—acquired immunodeficiency syndrome	0.000211	0.00473	CbGeAlD
Lansoprazole—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000204	0.00457	CbGeAlD
Lansoprazole—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000203	0.00454	CbGeAlD
Lansoprazole—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000199	0.00446	CbGeAlD
Lansoprazole—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000195	0.00437	CbGeAlD
Lansoprazole—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000192	0.0043	CbGeAlD
Lansoprazole—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000188	0.0042	CbGeAlD
Lansoprazole—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000185	0.00415	CbGeAlD
Lansoprazole—ABCB1—blood—acquired immunodeficiency syndrome	0.000177	0.00396	CbGeAlD
Lansoprazole—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000171	0.00383	CbGeAlD
Lansoprazole—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.00017	0.00381	CbGeAlD
Lansoprazole—ABCB1—vagina—acquired immunodeficiency syndrome	0.000164	0.00367	CbGeAlD
Lansoprazole—ABCB1—lung—acquired immunodeficiency syndrome	0.000155	0.00347	CbGeAlD
Lansoprazole—CYP2D6—brain—acquired immunodeficiency syndrome	0.000152	0.00341	CbGeAlD
Lansoprazole—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000143	0.00321	CbGeAlD
Lansoprazole—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000138	0.00309	CbGeAlD
Lansoprazole—ABCB1—brain—acquired immunodeficiency syndrome	0.00011	0.00245	CbGeAlD
Lansoprazole—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000106	0.00237	CbGeAlD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	6.98e-05	0.000286	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	6.96e-05	0.000285	CcSEcCtD
Lansoprazole—Pruritus—Abacavir—acquired immunodeficiency syndrome	6.95e-05	0.000285	CcSEcCtD
Lansoprazole—Fatigue—Indinavir—acquired immunodeficiency syndrome	6.95e-05	0.000285	CcSEcCtD
Lansoprazole—Anorexia—Delavirdine—acquired immunodeficiency syndrome	6.95e-05	0.000285	CcSEcCtD
Lansoprazole—Discomfort—Ritonavir—acquired immunodeficiency syndrome	6.95e-05	0.000285	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	6.94e-05	0.000284	CcSEcCtD
Lansoprazole—Cough—Saquinavir—acquired immunodeficiency syndrome	6.94e-05	0.000284	CcSEcCtD
Lansoprazole—Angioedema—Lamivudine—acquired immunodeficiency syndrome	6.93e-05	0.000284	CcSEcCtD
Lansoprazole—Pain—Indinavir—acquired immunodeficiency syndrome	6.89e-05	0.000282	CcSEcCtD
Lansoprazole—Constipation—Indinavir—acquired immunodeficiency syndrome	6.89e-05	0.000282	CcSEcCtD
Lansoprazole—Insomnia—Efavirenz—acquired immunodeficiency syndrome	6.89e-05	0.000282	CcSEcCtD
Lansoprazole—Urticaria—Zidovudine—acquired immunodeficiency syndrome	6.89e-05	0.000282	CcSEcCtD
Lansoprazole—Convulsion—Saquinavir—acquired immunodeficiency syndrome	6.89e-05	0.000282	CcSEcCtD
Lansoprazole—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	6.88e-05	0.000282	CcSEcCtD
Lansoprazole—Hypertension—Saquinavir—acquired immunodeficiency syndrome	6.86e-05	0.000281	CcSEcCtD
Lansoprazole—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	6.85e-05	0.000281	CcSEcCtD
Lansoprazole—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	6.85e-05	0.000281	CcSEcCtD
Lansoprazole—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	6.85e-05	0.00028	CcSEcCtD
Lansoprazole—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	6.84e-05	0.00028	CcSEcCtD
Lansoprazole—Malaise—Lamivudine—acquired immunodeficiency syndrome	6.84e-05	0.00028	CcSEcCtD
Lansoprazole—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	6.82e-05	0.00028	CcSEcCtD
Lansoprazole—Nausea—Didanosine—acquired immunodeficiency syndrome	6.82e-05	0.00028	CcSEcCtD
Lansoprazole—Vertigo—Lamivudine—acquired immunodeficiency syndrome	6.81e-05	0.000279	CcSEcCtD
Lansoprazole—Hypotension—Delavirdine—acquired immunodeficiency syndrome	6.81e-05	0.000279	CcSEcCtD
Lansoprazole—Syncope—Lamivudine—acquired immunodeficiency syndrome	6.8e-05	0.000279	CcSEcCtD
Lansoprazole—Confusional state—Ritonavir—acquired immunodeficiency syndrome	6.8e-05	0.000278	CcSEcCtD
Lansoprazole—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	6.79e-05	0.000278	CcSEcCtD
Lansoprazole—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	6.79e-05	0.000278	CcSEcCtD
Lansoprazole—Somnolence—Efavirenz—acquired immunodeficiency syndrome	6.77e-05	0.000277	CcSEcCtD
Lansoprazole—Chest pain—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.000277	CcSEcCtD
Lansoprazole—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.000277	CcSEcCtD
Lansoprazole—Myalgia—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.000277	CcSEcCtD
Lansoprazole—Anxiety—Saquinavir—acquired immunodeficiency syndrome	6.74e-05	0.000276	CcSEcCtD
Lansoprazole—Oedema—Ritonavir—acquired immunodeficiency syndrome	6.74e-05	0.000276	CcSEcCtD
Lansoprazole—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	6.72e-05	0.000275	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	6.72e-05	0.000275	CcSEcCtD
Lansoprazole—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	6.71e-05	0.000275	CcSEcCtD
Lansoprazole—Discomfort—Saquinavir—acquired immunodeficiency syndrome	6.69e-05	0.000274	CcSEcCtD
Lansoprazole—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	6.66e-05	0.000273	CcSEcCtD
Lansoprazole—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	6.64e-05	0.000272	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	6.64e-05	0.000272	CcSEcCtD
Lansoprazole—Shock—Ritonavir—acquired immunodeficiency syndrome	6.63e-05	0.000272	CcSEcCtD
Lansoprazole—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	6.62e-05	0.000271	CcSEcCtD
Lansoprazole—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	6.62e-05	0.000271	CcSEcCtD
Lansoprazole—Cough—Lamivudine—acquired immunodeficiency syndrome	6.62e-05	0.000271	CcSEcCtD
Lansoprazole—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	6.62e-05	0.000271	CcSEcCtD
Lansoprazole—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	6.61e-05	0.000271	CcSEcCtD
Lansoprazole—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	6.6e-05	0.00027	CcSEcCtD
Lansoprazole—Dizziness—Stavudine—acquired immunodeficiency syndrome	6.6e-05	0.00027	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	6.59e-05	0.00027	CcSEcCtD
Lansoprazole—Insomnia—Delavirdine—acquired immunodeficiency syndrome	6.59e-05	0.00027	CcSEcCtD
Lansoprazole—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	6.58e-05	0.00027	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	6.58e-05	0.000269	CcSEcCtD
Lansoprazole—Convulsion—Lamivudine—acquired immunodeficiency syndrome	6.57e-05	0.000269	CcSEcCtD
Lansoprazole—Vomiting—Nevirapine—acquired immunodeficiency syndrome	6.57e-05	0.000269	CcSEcCtD
Lansoprazole—Fatigue—Efavirenz—acquired immunodeficiency syndrome	6.57e-05	0.000269	CcSEcCtD
Lansoprazole—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	6.55e-05	0.000268	CcSEcCtD
Lansoprazole—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	6.54e-05	0.000268	CcSEcCtD
Lansoprazole—Confusional state—Saquinavir—acquired immunodeficiency syndrome	6.54e-05	0.000268	CcSEcCtD
Lansoprazole—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	6.52e-05	0.000267	CcSEcCtD
Lansoprazole—Constipation—Efavirenz—acquired immunodeficiency syndrome	6.51e-05	0.000267	CcSEcCtD
Lansoprazole—Pain—Efavirenz—acquired immunodeficiency syndrome	6.51e-05	0.000267	CcSEcCtD
Lansoprazole—Rash—Nevirapine—acquired immunodeficiency syndrome	6.51e-05	0.000267	CcSEcCtD
Lansoprazole—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	6.51e-05	0.000267	CcSEcCtD
Lansoprazole—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	6.5e-05	0.000266	CcSEcCtD
Lansoprazole—Dizziness—Abacavir—acquired immunodeficiency syndrome	6.5e-05	0.000266	CcSEcCtD
Lansoprazole—Oedema—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000266	CcSEcCtD
Lansoprazole—Somnolence—Delavirdine—acquired immunodeficiency syndrome	6.48e-05	0.000265	CcSEcCtD
Lansoprazole—Headache—Nevirapine—acquired immunodeficiency syndrome	6.47e-05	0.000265	CcSEcCtD
Lansoprazole—Myalgia—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000265	CcSEcCtD
Lansoprazole—Chest pain—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000265	CcSEcCtD
Lansoprazole—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000265	CcSEcCtD
Lansoprazole—Infection—Saquinavir—acquired immunodeficiency syndrome	6.44e-05	0.000264	CcSEcCtD
Lansoprazole—Anxiety—Lamivudine—acquired immunodeficiency syndrome	6.43e-05	0.000264	CcSEcCtD
Lansoprazole—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.42e-05	0.000263	CcSEcCtD
Lansoprazole—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.42e-05	0.000263	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.41e-05	0.000263	CcSEcCtD
Lansoprazole—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.41e-05	0.000262	CcSEcCtD
Lansoprazole—Shock—Saquinavir—acquired immunodeficiency syndrome	6.38e-05	0.000262	CcSEcCtD
Lansoprazole—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.38e-05	0.000261	CcSEcCtD
Lansoprazole—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.37e-05	0.000261	CcSEcCtD
Lansoprazole—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.37e-05	0.000261	CcSEcCtD
Lansoprazole—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.36e-05	0.000261	CcSEcCtD
Lansoprazole—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.36e-05	0.000261	CcSEcCtD
Lansoprazole—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.35e-05	0.00026	CcSEcCtD
Lansoprazole—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.34e-05	0.00026	CcSEcCtD
Lansoprazole—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.34e-05	0.00026	CcSEcCtD
Lansoprazole—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	6.31e-05	0.000259	CcSEcCtD
Lansoprazole—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.31e-05	0.000258	CcSEcCtD
Lansoprazole—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.3e-05	0.000258	CcSEcCtD
Lansoprazole—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.3e-05	0.000258	CcSEcCtD
Lansoprazole—Hypotension—Ritonavir—acquired immunodeficiency syndrome	6.3e-05	0.000258	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.29e-05	0.000258	CcSEcCtD
Lansoprazole—Rash—Stavudine—acquired immunodeficiency syndrome	6.29e-05	0.000258	CcSEcCtD
Lansoprazole—Fatigue—Delavirdine—acquired immunodeficiency syndrome	6.28e-05	0.000257	CcSEcCtD
Lansoprazole—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.28e-05	0.000257	CcSEcCtD
Lansoprazole—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.28e-05	0.000257	CcSEcCtD
Lansoprazole—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.27e-05	0.000257	CcSEcCtD
Lansoprazole—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.27e-05	0.000257	CcSEcCtD
Lansoprazole—Headache—Stavudine—acquired immunodeficiency syndrome	6.25e-05	0.000256	CcSEcCtD
Lansoprazole—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.25e-05	0.000256	CcSEcCtD
Lansoprazole—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.24e-05	0.000256	CcSEcCtD
Lansoprazole—Pain—Delavirdine—acquired immunodeficiency syndrome	6.23e-05	0.000255	CcSEcCtD
Lansoprazole—Constipation—Delavirdine—acquired immunodeficiency syndrome	6.23e-05	0.000255	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.23e-05	0.000255	CcSEcCtD
Lansoprazole—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.22e-05	0.000255	CcSEcCtD
Lansoprazole—Rash—Abacavir—acquired immunodeficiency syndrome	6.2e-05	0.000254	CcSEcCtD
Lansoprazole—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.19e-05	0.000254	CcSEcCtD
Lansoprazole—Oedema—Lamivudine—acquired immunodeficiency syndrome	6.19e-05	0.000254	CcSEcCtD
Lansoprazole—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	6.19e-05	0.000254	CcSEcCtD
Lansoprazole—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.18e-05	0.000253	CcSEcCtD
Lansoprazole—Headache—Abacavir—acquired immunodeficiency syndrome	6.16e-05	0.000252	CcSEcCtD
Lansoprazole—Infection—Lamivudine—acquired immunodeficiency syndrome	6.15e-05	0.000252	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.14e-05	0.000252	CcSEcCtD
Lansoprazole—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.14e-05	0.000251	CcSEcCtD
Lansoprazole—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.13e-05	0.000251	CcSEcCtD
Lansoprazole—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.1e-05	0.00025	CcSEcCtD
Lansoprazole—Shock—Lamivudine—acquired immunodeficiency syndrome	6.09e-05	0.000249	CcSEcCtD
Lansoprazole—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.07e-05	0.000249	CcSEcCtD
Lansoprazole—Hypotension—Saquinavir—acquired immunodeficiency syndrome	6.06e-05	0.000248	CcSEcCtD
Lansoprazole—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.06e-05	0.000248	CcSEcCtD
Lansoprazole—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.05e-05	0.000248	CcSEcCtD
Lansoprazole—Urticaria—Efavirenz—acquired immunodeficiency syndrome	6.05e-05	0.000248	CcSEcCtD
Lansoprazole—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.02e-05	0.000247	CcSEcCtD
Lansoprazole—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.02e-05	0.000247	CcSEcCtD
Lansoprazole—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.01e-05	0.000246	CcSEcCtD
Lansoprazole—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.01e-05	0.000246	CcSEcCtD
Lansoprazole—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.01e-05	0.000246	CcSEcCtD
Lansoprazole—Somnolence—Ritonavir—acquired immunodeficiency syndrome	5.99e-05	0.000246	CcSEcCtD
Lansoprazole—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.98e-05	0.000245	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.96e-05	0.000244	CcSEcCtD
Lansoprazole—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.94e-05	0.000243	CcSEcCtD
Lansoprazole—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.94e-05	0.000243	CcSEcCtD
Lansoprazole—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.93e-05	0.000243	CcSEcCtD
Lansoprazole—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.93e-05	0.000243	CcSEcCtD
Lansoprazole—Nausea—Stavudine—acquired immunodeficiency syndrome	5.92e-05	0.000243	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.91e-05	0.000242	CcSEcCtD
Lansoprazole—Anorexia—Lamivudine—acquired immunodeficiency syndrome	5.9e-05	0.000242	CcSEcCtD
Lansoprazole—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.87e-05	0.00024	CcSEcCtD
Lansoprazole—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.86e-05	0.00024	CcSEcCtD
Lansoprazole—Nausea—Abacavir—acquired immunodeficiency syndrome	5.84e-05	0.000239	CcSEcCtD
Lansoprazole—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.83e-05	0.000239	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.82e-05	0.000238	CcSEcCtD
Lansoprazole—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.81e-05	0.000238	CcSEcCtD
Lansoprazole—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.79e-05	0.000237	CcSEcCtD
Lansoprazole—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.78e-05	0.000237	CcSEcCtD
Lansoprazole—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.78e-05	0.000237	CcSEcCtD
Lansoprazole—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.78e-05	0.000237	CcSEcCtD
Lansoprazole—Somnolence—Saquinavir—acquired immunodeficiency syndrome	5.77e-05	0.000236	CcSEcCtD
Lansoprazole—Pain—Ritonavir—acquired immunodeficiency syndrome	5.76e-05	0.000236	CcSEcCtD
Lansoprazole—Constipation—Ritonavir—acquired immunodeficiency syndrome	5.76e-05	0.000236	CcSEcCtD
Lansoprazole—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.76e-05	0.000236	CcSEcCtD
Lansoprazole—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.76e-05	0.000236	CcSEcCtD
Lansoprazole—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.73e-05	0.000235	CcSEcCtD
Lansoprazole—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	5.71e-05	0.000234	CcSEcCtD
Lansoprazole—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.7e-05	0.000234	CcSEcCtD
Lansoprazole—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.64e-05	0.000231	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.64e-05	0.000231	CcSEcCtD
Lansoprazole—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.61e-05	0.00023	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.6e-05	0.000229	CcSEcCtD
Lansoprazole—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.6e-05	0.000229	CcSEcCtD
Lansoprazole—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.59e-05	0.000229	CcSEcCtD
Lansoprazole—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.56e-05	0.000228	CcSEcCtD
Lansoprazole—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.55e-05	0.000228	CcSEcCtD
Lansoprazole—Constipation—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000227	CcSEcCtD
Lansoprazole—Pain—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000227	CcSEcCtD
Lansoprazole—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.000226	CcSEcCtD
Lansoprazole—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	5.52e-05	0.000226	CcSEcCtD
Lansoprazole—Vomiting—Zidovudine—acquired immunodeficiency syndrome	5.51e-05	0.000226	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	5.51e-05	0.000226	CcSEcCtD
Lansoprazole—Somnolence—Lamivudine—acquired immunodeficiency syndrome	5.5e-05	0.000225	CcSEcCtD
Lansoprazole—Rash—Zidovudine—acquired immunodeficiency syndrome	5.47e-05	0.000224	CcSEcCtD
Lansoprazole—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.47e-05	0.000224	CcSEcCtD
Lansoprazole—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.46e-05	0.000224	CcSEcCtD
Lansoprazole—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.45e-05	0.000223	CcSEcCtD
Lansoprazole—Headache—Zidovudine—acquired immunodeficiency syndrome	5.43e-05	0.000223	CcSEcCtD
Lansoprazole—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.39e-05	0.000221	CcSEcCtD
Lansoprazole—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.38e-05	0.00022	CcSEcCtD
Lansoprazole—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.37e-05	0.00022	CcSEcCtD
Lansoprazole—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.35e-05	0.000219	CcSEcCtD
Lansoprazole—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.35e-05	0.000219	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.34e-05	0.000219	CcSEcCtD
Lansoprazole—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.34e-05	0.000219	CcSEcCtD
Lansoprazole—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.33e-05	0.000218	CcSEcCtD
Lansoprazole—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.33e-05	0.000218	CcSEcCtD
Lansoprazole—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.33e-05	0.000218	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.3e-05	0.000217	CcSEcCtD
Lansoprazole—Pain—Lamivudine—acquired immunodeficiency syndrome	5.29e-05	0.000217	CcSEcCtD
Lansoprazole—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.29e-05	0.000217	CcSEcCtD
Lansoprazole—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.23e-05	0.000214	CcSEcCtD
Lansoprazole—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.21e-05	0.000214	CcSEcCtD
Lansoprazole—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.16e-05	0.000211	CcSEcCtD
Lansoprazole—Urticaria—Saquinavir—acquired immunodeficiency syndrome	5.15e-05	0.000211	CcSEcCtD
Lansoprazole—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.15e-05	0.000211	CcSEcCtD
Lansoprazole—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.13e-05	0.00021	CcSEcCtD
Lansoprazole—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.13e-05	0.00021	CcSEcCtD
Lansoprazole—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.13e-05	0.00021	CcSEcCtD
Lansoprazole—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.1e-05	0.000209	CcSEcCtD
Lansoprazole—Rash—Indinavir—acquired immunodeficiency syndrome	5.08e-05	0.000208	CcSEcCtD
Lansoprazole—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.08e-05	0.000208	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.06e-05	0.000207	CcSEcCtD
Lansoprazole—Headache—Indinavir—acquired immunodeficiency syndrome	5.05e-05	0.000207	CcSEcCtD
Lansoprazole—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.04e-05	0.000206	CcSEcCtD
Lansoprazole—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.99e-05	0.000204	CcSEcCtD
Lansoprazole—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.97e-05	0.000203	CcSEcCtD
Lansoprazole—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.92e-05	0.000201	CcSEcCtD
Lansoprazole—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.0002	CcSEcCtD
Lansoprazole—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.0002	CcSEcCtD
Lansoprazole—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.84e-05	0.000198	CcSEcCtD
Lansoprazole—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.84e-05	0.000198	CcSEcCtD
Lansoprazole—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.82e-05	0.000197	CcSEcCtD
Lansoprazole—Rash—Efavirenz—acquired immunodeficiency syndrome	4.8e-05	0.000197	CcSEcCtD
Lansoprazole—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.8e-05	0.000197	CcSEcCtD
Lansoprazole—Nausea—Indinavir—acquired immunodeficiency syndrome	4.79e-05	0.000196	CcSEcCtD
Lansoprazole—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.78e-05	0.000196	CcSEcCtD
Lansoprazole—Headache—Efavirenz—acquired immunodeficiency syndrome	4.77e-05	0.000196	CcSEcCtD
Lansoprazole—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.77e-05	0.000195	CcSEcCtD
Lansoprazole—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.65e-05	0.000191	CcSEcCtD
Lansoprazole—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.63e-05	0.00019	CcSEcCtD
Lansoprazole—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.61e-05	0.000189	CcSEcCtD
Lansoprazole—Rash—Delavirdine—acquired immunodeficiency syndrome	4.6e-05	0.000188	CcSEcCtD
Lansoprazole—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.59e-05	0.000188	CcSEcCtD
Lansoprazole—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.59e-05	0.000188	CcSEcCtD
Lansoprazole—Headache—Delavirdine—acquired immunodeficiency syndrome	4.57e-05	0.000187	CcSEcCtD
Lansoprazole—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.56e-05	0.000187	CcSEcCtD
Lansoprazole—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.52e-05	0.000185	CcSEcCtD
Lansoprazole—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.46e-05	0.000183	CcSEcCtD
Lansoprazole—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.44e-05	0.000182	CcSEcCtD
Lansoprazole—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.44e-05	0.000182	CcSEcCtD
Lansoprazole—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.38e-05	0.000179	CcSEcCtD
Lansoprazole—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.33e-05	0.000177	CcSEcCtD
Lansoprazole—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.29e-05	0.000176	CcSEcCtD
Lansoprazole—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.29e-05	0.000176	CcSEcCtD
Lansoprazole—Rash—Ritonavir—acquired immunodeficiency syndrome	4.25e-05	0.000174	CcSEcCtD
Lansoprazole—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.25e-05	0.000174	CcSEcCtD
Lansoprazole—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.23e-05	0.000173	CcSEcCtD
Lansoprazole—Headache—Ritonavir—acquired immunodeficiency syndrome	4.22e-05	0.000173	CcSEcCtD
Lansoprazole—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.12e-05	0.000169	CcSEcCtD
Lansoprazole—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.09e-05	0.000168	CcSEcCtD
Lansoprazole—Rash—Saquinavir—acquired immunodeficiency syndrome	4.09e-05	0.000168	CcSEcCtD
Lansoprazole—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.09e-05	0.000167	CcSEcCtD
Lansoprazole—Headache—Saquinavir—acquired immunodeficiency syndrome	4.06e-05	0.000167	CcSEcCtD
Lansoprazole—Nausea—Ritonavir—acquired immunodeficiency syndrome	4e-05	0.000164	CcSEcCtD
Lansoprazole—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.93e-05	0.000161	CcSEcCtD
Lansoprazole—Rash—Lamivudine—acquired immunodeficiency syndrome	3.9e-05	0.00016	CcSEcCtD
Lansoprazole—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.9e-05	0.00016	CcSEcCtD
Lansoprazole—Headache—Lamivudine—acquired immunodeficiency syndrome	3.88e-05	0.000159	CcSEcCtD
Lansoprazole—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.85e-05	0.000158	CcSEcCtD
Lansoprazole—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.68e-05	0.000151	CcSEcCtD
